Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 7/20 | 1.00 |
| ▸ | KDR | P35968 | 10/20 | 0.66 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21277765 | 0.95 | TGFBR1 (0.90) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL21734155 | 0.82 | TGFBR1 (0.69) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL21733970 | 0.80 | TGFBR1 (0.66) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL20158848 | 0.79 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL20074464 | 0.79 | TGFBR1 (1.00) | TGFBR1MAPK14KDR | |
| SCHEMBL20074503 | 0.79 | TGFBR1 (1.00) | TGFBR1MAPK14KDR | |
| SCHEMBL20074459 | 0.79 | TGFBR1 (1.00) | TGFBR1MAPK14KDR | |
| SCHEMBL20158913 | 0.76 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL20158959 | 0.76 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL20074373 | 0.75 | TGFBR1 (0.65) | TGFBR1MAPK14KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| EP-3527570-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-3527570-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018068759-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | TGFBR1, TGFB2, TGFB1 | TGFBR1 1/4885MAPK14 1887/4885KDR 227/4885 |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TGFBR1, TGFB2, TGFB1 | TGFBR1 1/4885MAPK14 1887/4885KDR 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.